Search Results

ProSciento, Inc. is pleased to announce that they are a recipient of the 2023 Innovation Award from The Liver Coalition of San Diego, champions for liver health and patient support in the region.

ProSciento, Inc., a leading specialty clinical research organization (CRO) exclusively focused on metabolic diseases, today announced the appointment of David Sockolof to the role of Chief Financial Officer (CFO).

ProSciento, Inc., a leading specialty clinical research organization exclusively focused on NASH, diabetes, obesity and related metabolic diseases, announced the appointment of Stephen Mullennix to the role of Chief Financial Officer.

ProSciento, Inc., a leading specialty clinical research organization (CRO) focused on non-alcoholic steatohepatitis (NASH), diabetes, obesity, and related metabolic diseases, announced today the closing of a growth financing from 1315 Capital, a healthcare investment firm that provides expansion and growth capital to commercial-stage healthcare services, medical technology and specialty therapeutics compani

HPCTC enters a multi-year partnership to establish a database enriched for subjects with NAFLD/NASH as a member of ProSciento’s NASH PASS Site Network

ProSciento, Inc. announced the appointment of Brian Mooney to the role of Chief Operating Officer (COO).

Nieto joins ProSciento from the CRO PPD, where he served as Executive Director of Early Phase Business Development.

ProSciento, Inc. announced the appointment of Dr. Carine Beysen as Senior Director of Clinical Research Innovation (CRI) Services.

ProSciento, Inc. announced today the formation of a NASH Roundtable, bringing together leading scientific and clinical development experts to advance science, methods and strategies for NASH clinical and pre-clinical research.